Name: 16th January 2024 – GLP-1 weight-loss drugs
Start: 2024-01-30T14:51:00Z
End: 2024-01-30T14:51:15.000Z
Location: BrightTALK
Rating: 0

Managers will discuss why innovation remains an important driver for investment as well as a some of the specific innovation frontiers they consider most compelling.

WS Amati Global Innovation Fund Update

Amati AIM IHT Portfolio Service Update

WS Amati UK Listed Smaller Companies Fund Update

Buybacks, Bids and Beta - Capturing the Upside in UK Smallcap

Amati managers Mikhail Zverev and Graeme Bencke are back from Hannover Messe, a leading global trade show dedicated to automation and industrial technology.

On this call they showcase some footage from the event, discuss the state of demand and innovation in the industrial technology sector and consider the implications for equity investors and our Global Innovation Fund.

7th May 2024 - Innovation in industrial technology: insights from Hannover Messe

The geopolitics of the unexpected gold price boom.

A conversation between Paul Jourdan, CEO of Amati Global Investors and Kieron Hodgson, Managing Director, Commodities & Mining Research at Panmure Gordon.

Amati Insights - 23rd April 2024

There is a necessary link between patience and successful long-term investing in metals and mining. Due to the volatility and cyclicality  of resource investment, patience differentiates between long-horizon and short-horizon investors. Patience has value, because it supports the ability to invest for the long term and allows the maintenance of losing positions. Second, patience running out is bad, because it can trigger a value-destructive sale (capitulation) and sends the wrong signals, which can undermine the capacity to exercise patience in the future.

Resource investors tend to be value investors, held at ransom by the vagaries of the market and risk off sentiment. However,  it is important to recognise when the market is driven by sentiment and take advantage of it for long term value. Global geopolitical and fiscal risk has never been higher, combined with the need to decarbonize global energy, the two main book ends to the Amati Strategic Metals Fund remain key investment areas. Georges and Mark will highlight the opportunities the market currently offers resource investors.

The Role of the Patient Resource Investor

Recent geopolitical tensions and the disruptions through the pandemic have highlighted the risks of relying on globalised supply chains. The result is a wave of ‘reshoring’ and ‘near-shoring’ of production to avoid these problems in the future. Join David Stevenson and Graeme Bencke in the latest Amati Insights call as they discuss investing in the potential beneficiaries of this process.

9th April 2024 - Risks of Relying on Globalised Supply Chains

In March, the US FDA approved a next generation surgical robot, the 5th generation Da Vinci robot, developed by Intuitive Surgical. This showcases rapid progress in “robotic assisted surgery”, an exciting Innovation Frontier that is transforming surgery field.

Join Dr Gareth Blades and Mikhail Zverev as they discuss why this is important, who the leading players are in this sector and what opportunities this presents for global and UK equity investors.

26th March 2024 - Robotic Surgery

Big tech may get all the headlines, but innovation in healthcare is also progressing at a rapid pace. This week, Gareth and Mikhail from the Amati Global Innovation team discuss recent findings from a leading global healthcare conference.

12th March 2024 - Innovation in healthcare

“Magnificent 7," largest US technology stocks, continue to dominate US and Global markets performance. Graeme Bencke and Mikhail Zverev will look at the underlying drivers, valuations and fundamentals behind this group of companies and discuss the world of innovation opportunities that lie beyond.

27th February 2024 - Magnificent 7

After several years of outflows we are now seeing early signs of recovery in the UK smaller companies sector. Scott McKenzie and David Stevenson examine why increasing share buybacks and healthy dividend yields are helping to underpin the compelling valuations now on offer across the asset class.

13th February 2024 - UK Smallcap Buybacks & Dividends

Q&A with Fund Manager, Graeme Bencke.

The full report can be accessed via our website - https://www.amatiglobal.com/media/quarterly-review-ws-amati-strategic-innovation-fund-q4-2023/

Quarterly Review: WS Amati Global Innovation Fund - Q4 2023

Q&A with Fund Manager, Mark Smith.

The full report can be accessed via our website - https://www.amatiglobal.com/media/quarterly-review-ws-amati-strategic-metals-fund-q4-2023/

Quarterly Review: WS Amati Strategic Metals Fund - Q4 2023

Q&A with Fund Manager, Scott McKenzie.

The full report can be accessed via our website - https://www.amatiglobal.com/media/quarterly-review-ws-amati-uk-listed-smaller-companies-fund-q4-2023/

Quarterly Review: WS Amati UK Listed Companies Fund - Q4 2023

The nature of warfare is changing and emerging new threats demand innovative technological solutions from the armed forces and the defence industry. Join David Stevenson and Graeme Bencke for an overview of what this means for the Aerospace and Defence sector and the opportunities this brings to UK and Global equity investors.

30th January 2024 – Innovation and the changing nature of warfare

Before we break for Christmas and New Year, Paul Jourdan and Mikhail Zverev look back on 2023, share their observations on UK and global equity markets and talk about what they have changed in their positioning and the outlook for investors in 2024.

12th December 2023 – 2023 in the UK and Global markets – a year to forget?

Radio Frequency Identification technology is starting to change our everyday life. It enables automated self-check-outs at retailers Uniqlo and Zara and will power parcel tracking at UPS. In more specialist applications it will drive safer pharmaceuticals supply chain, auto parts quality control and EV battery recycling. Amati managers Graeme Bencke and Mikhail Zverev discuss why RFID matters and what opportunities do they see to benefit from this technological change.

28th November 2023 – Radio Frequency Identification Technology

14th November 2023 – Investing in Semiconductor Industry

31st October 2023 – Opportunities in Photonics Industry

3rd October 2023 – Diluting Net Zero Commitments

19th September 2023 – Bioprocessing

5th September 2023 – Where do we go from here?

27th June 2023 – Our Summer Research To-Do List

13th June 2023 – Commercial Real Estate

30th May 2023 – Innovation in Life Sciences

16th May 2023 – Trends and opportunities across Global & UK Markets

2nd May 2023 – Electric Vehicle Market

18th April 2023 - ChatGPT

4th April 2023 - Machine Vision

21st March 2023 - Silicon Valley Bank

7th March 2023 - Lithium

21st February 2023 - Nuclear Energy

7th February 2023 - Digital Advertising

24th January 2023 - Defence Spending

Amati Insights

Join Dr Gareth Blades & Graeme Bencke as they discuss the outlook for the new, much publicised ‘GLP-1’ weight-loss drugs. What are they, how the competing products differ, and what are the implications for other weight and diabetes management approaches and the broader healthcare system.

16th January 2024 – GLP-1 weight-loss drugs

GLP-1

Weight Loss Drugs

Healthcare

Diabetes

Fund Manager

This community is for investors who work within the European market providing client and portfolio management advice. Join to learn from trusted investors on the latest trends and account strategies for delivering consistent results and long term success.

European Investors

The accounting and finance community on BrightTALK features presentations from leading accountants and finance professionals. The accounting community includes tax planning strategies, QuickBooks webinars and other accounting webinars, while the finance community features presentations on financial capital regulations and forensic data analytics. Join the conversation by attending live financial and accounting presentations and connecting with industry thought leaders.

16th January 2024 – GLP-1 weight-loss drugs

Presented by

About this talk

More from this channel